Sarasota Memorial Surgeons Performed Dual Cardiac Implants
A medical team successfully implanted a new valve and stroke-prevention device in one patient.
Updated on Oct. 13, 2026 in Heart Disease
Live Poll
Do you trust that new medical device combinations will improve long-term heart health?
Surgeons at Sarasota Memorial performed a procedure combining the TRIFORMIS RESILIA valve and the ECLIPTIS system. This dual-implant approach allowed doctors to replace a diseased valve and address stroke risk in a single operation.
Why it matters
The combination procedure avoids the need for separate surgeries to manage two distinct heart conditions. By streamlining the intervention, surgeons reduce the total time a patient spends under anesthesia and recovery.
Sarasota Memorial performed these procedures using the TRIFORMIS RESILIA valve, approved in May 2026, and the ECLIPTIS system, cleared in June 2026. Surgeons utilized two implants in one patient and ECLIPTIS systems in two additional cases.
The players
Dr. Jonathan Hoffberger
He is a surgeon at Sarasota Memorial who performed the combination procedure involving two cardiac implants.
Dr. Jeffrey Sell
He is a surgeon at Sarasota Memorial who conducted ECLIPTIS system implants.
Dr. Kristen Walker
She is a surgeon at Sarasota Memorial who performed ECLIPTIS system implants.
Sarasota Memorial
This is a medical facility in Sarasota that utilizes advanced cardiac technologies for patient care.
Food and Drug Administration
This federal agency is responsible for protecting public health by regulating medical devices.
The details
The procedure replaces a diseased tricuspid valve with the TRIFORMIS RESILIA valve while utilizing the ECLIPTIS system to close the left atrial appendage. Surgeons previously adapted valves designed for other cardiac positions to manage these cases, but the current approach uses specialized technology for each specific heart function.
Timeline
May 2026: The Food and Drug Administration approved the TRIFORMIS RESILIA valve.
June 2026: The Food and Drug Administration cleared the ECLIPTIS system.
October 13, 2026: Sarasota Memorial announced the completion of the procedures.
The Big Picture
This procedure follows the regulatory framework established by the FDA 510(k) medical device clearance process, which permits hospitals to integrate newly approved implants into clinical practice. The implementation of these devices marks the direct clinical application of the regulatory milestones set by the FDA 510(k) medical device clearance process.
This procedure offers patients with complex heart issues a more efficient treatment path by combining two distinct interventions into one surgery. It potentially lowers the overall burden of care for individuals requiring both valve replacement and stroke-risk management.
The takeaway
These procedures demonstrate how advanced cardiac implants can be combined to optimize patient outcomes in a single clinical visit. Patients should discuss their eligibility for such combined interventions with their medical specialists during routine cardiac evaluations.
Further reading
For more information on the management of heart conditions, visit the Heart Disease section.
Source note: This article includes information reported by Mysuncoast.
Live Poll
Do you trust that new medical device combinations will improve long-term heart health?
